ストックスクリーナーアプリを入手
0.3128
1.29%
0.00165
前日終値:
$0.3111
開ける：
$0.319
24時間の取引高:
6,519
Relative Volume:
0.04
時価総額：
$19.80M
収益：
$37.20M
当期純損益:
$-11.85M
株価収益率:
-1.6392
EPS:
-0.1908
ネットキャッシュフロー:
$-10.59M
1週間 パフォーマンス:
-21.21%
1か月 パフォーマンス:
-19.94%
6か月 パフォーマンス:
-50.78%
1年 パフォーマンス:
-62.67%
1日の値動き範囲:
$0.3151
$0.3484
1週間の範囲:
$0.3003
$0.40
52週間の値動き範囲:
$0.3003
$1.04
Cytosorbents Corp Stock (CTSO) Company Profile
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.3151 | 22.37M | 37.20M | -11.85M | -10.59M | -0.1908 |
ABT
Abbott Laboratories
|
114.75 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.92 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.36 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.62 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.54 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-07 | 開始されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2020-09-17 | 開始されました | Jefferies | Buy |
| 2020-09-01 | 開始されました | SVB Leerink | Outperform |
| 2017-08-08 | 繰り返されました | Maxim Group | Buy |
| 2016-10-26 | 開始されました | Aegis Capital | Buy |
| 2016-05-24 | 開始されました | Maxim Group | Buy |
| 2015-10-29 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 繰り返されました | MLV & Co | Buy |
| 2015-04-01 | 繰り返されました | MLV & Co | Buy |
| 2015-03-05 | 開始されました | MLV & Co | Buy |
| 2015-02-25 | 開始されました | WBB Securities | Speculative Buy |
| 2015-01-27 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Cytosorbents Corp (CTSO) 最新ニュース
Cytosorbents (CTSO) Financial Update: EPS Comes in Below Forecast; Market Follow-Through: Shares Finish 4.56% LowerEarnings Season Outlook - Vinanet
CytoSorbents (CTSO) wins approval for reverse split and director slate at 2026 meeting - Stock Titan
Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Cytosorbents Corp. R (HQE1.DU) Q1 FY2026 earnings call transcript - Yahoo Finance
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q2 2026 Cytosorbents Corp Earnings Call Transcript - GuruFocus
Cytosorbents Corp (CTSO) Stock News Today - TradingKey
CytoSorbents posts $9.6M Q2 revenue, narrows cash burn and advances DrugSorb-ATR regulatory path - TradingView
Cytosorbents Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nea - GuruFocus
Is CytoSorbents Corp (CTSO) a Value Opportunity After Q2 Earning - GuruFocus
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ... - finance.yahoo.com
Earnings call transcript: Cytosorbents posts modest Q2 2026 revenue beat - Investing.com
Cytosorbents : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Cytosorbents Corp reports results for the quarter ended June 30Earnings Summary - TradingView
CytoSorbents Q2 2026 earnings: Margins improve despite flat revenue - TradingKey
CytoSorbents: Q2 Earnings Snapshot - marketscreener.com
Cytosorbents Corp 2Q 2026: Revenue $9.63M, EPS ($0.07) — 10-Q Summary - TradingView
Cytosorbents Corp. R (HQE1.DU) Q2 FY2026 earnings call transcript - Yahoo Finance
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - PR Newswire
CytoSorbents (Nasdaq: CTSO) flags going concern as cash falls to $5.9M - Stock Titan
Cytosorbents Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Cytosorbents Corp (CTSO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytoSorbents Market Sentiment - Benzinga España
Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTSO|Cytosorbents Corp|Price:0.360|Chg%:-0.001 - TradingKey
TradingKey - TradingKey
Cytosorbents Corp (CTSO) Cash Flow - TradingKey
CTSO|Cytosorbents Corp|Price:0.360| - TradingKey
Cytosorbents Corp (CTSO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CTSO|Cytosorbents Corp|Price:0.361|Chg%:-0.021 - TradingKey
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - BioSpace
CytoSorbents (CTSO) to Release Q2 Financial Results on July 30 - GuruFocus
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure - Stock Titan
CTSO | Cytosorbents Corp. Executive Compensation - Quiver Quantitative
[ARS] Cytosorbents Corp SEC Filing - Stock Titan
CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing - Stock Titan
CytoSorbents (NASDAQ: CTSO) Targets Major ICU & Cardiac Surgery Markets With Breakthrough Blood Purification Tech, Eyes 2026 Cash Flow Breakeven and FDA Approval 246 - Minichart
CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs - TradingView
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals - Stock Titan
Cytosorbents Corp (CTSO) Institutional Confidence - TradingKey
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026 - Yahoo Finance
Cytosorbents Corp (CTSO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytosorbents Corp (CTSO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytosorbents Corp (CTSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytosorbents (CTSO) Drops 9% as Shares Test Key Support at $0.45PCR Mean Reversion - dars.gov.et
Cytosorbents CFO Peter Mariani buys $44,000 in stock - Investing.com UK
Cytosorbents CFO Peter Mariani buys $44,000 in stock By Investing.com - Investing.com India
Cytosorbents (CTSO) CFO Peter Mariani buys 100,000 shares in open market - Stock Titan
Cytosorbents Corp (CTSO) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.75%
大文字化:
|
ボリューム (24 時間):